ArticleScientific reports2026
Correlation between statin use and 30 day mortality in patients with acute kidney injury after intracerebral hemorrhage: a retrospective analysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a frequent complication in patients with nontraumatic intracerebral hemorrhage (ICH). Previous studies have suggested that statins may improve survival in patients with AKI. This study investigated the association between statin therapy and 30 day all-cause mortality in patients with ICH. Patients with both nontraumatic intracerebral hemorrhage and acute kidney injury (ICH-AKI) were identified from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database. After intensive care unit (ICU) admission, patients were categorized into statin and non-statin groups based on their statin use. To assess the effect of statin therapy on 30-day mortality, we first accounted for baseline differences using both propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). Then, we performed multivariate regression and subgroup analyses on the balanced cohorts. Among 1805 patients with ICH-AKI, 654 received statin therapy. Compared with those who did not receive statins, statin users were older, had a higher proportion of males, and exhibited a lower 30 day mortality rate. After adjustment for demographic and clinical covariates, a significant survival benefit was observed in the statin group via Kaplan-Meier analysis (p < 0.0001). This finding was robustly confirmed by a multivariate Cox model [hazard ratio (HR) = 0.48; 95% confidence interval (CI): 0.37-0.62; P < 0.001]. Consistent with this, subgroup analyses affirmed the protective association of statin use in ICH-AKI patients. Statin therapy in the ICU was associated with reduced 30 day all-cause mortality in patients with ICH-AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.